The PFP products protect medicines from contamination. They include a combination of a formulation without chemical preservatives, a pump system that filters or blocks the returning air, and an actuator that prevents bacterial ingress into the dispenser.
MWV says the five-fold mechanical protection system assures germ-free pump dosing to the patient. It includes non-return valves next to the orifice bore and in the metering chamber, and a filter element for contamination-free ventilation of the container, a locked actuator, and a sealed air path during storage.
The PFP T delivers volumes from 0.05mL to 0.14mL. Upside down and tamper-evident features are also available with the product.
‘We are expanding the range of preservative free pumps to meet consumer demand for preservative-free formulations,’ said Chris Hall, vice president and managing director, Medical Plastics Division, MWV Healthcare.
‘This technology does more than protect preservative free medicines from contamination, it is also suitable for use with other topical or dermal products where protecting the formulation and maintaining sterility is important, and necessary.’
MWV Healthcare expands preservative free pumps line
Manufacturing facility awarded certification for PFP spray systems
You may also like
Trending Articles
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Drug Delivery
Stevanato Group launches Deora pen injector platform targeting GLP-1 and incretin therapies
The fixed-dose, multi-use pull-push device accommodates volumes up to 0.75 mL, offering pharma partners a scalable, error-reducing delivery solution for diabetes and weight management programmes
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza